CN102552436A - Medicine for treating anxiety and depressive disorder as well as application of medicine - Google Patents
Medicine for treating anxiety and depressive disorder as well as application of medicine Download PDFInfo
- Publication number
- CN102552436A CN102552436A CN2012100053141A CN201210005314A CN102552436A CN 102552436 A CN102552436 A CN 102552436A CN 2012100053141 A CN2012100053141 A CN 2012100053141A CN 201210005314 A CN201210005314 A CN 201210005314A CN 102552436 A CN102552436 A CN 102552436A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- anxiety
- treatment
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating anxiety and depressive disorder, which is prepared by the following crude medicines according to parts by weight: 6-20 parts of radix bupleuri, 6-20 parts of radix paeoniae alba and 6-15 parts of white atractylodes rhizome; and the medicine further comprises 6-15 parts of selfheal, 3-6 parts of coptis chinensis and 3-6 parts of cinnamon. The invention further provides an application of the medicine in preparing medicine for treating anxiety and depressive disorder. The medicine is prepared by pure traditional Chinese medicine and based on enough traditional Chinese medicine and western medicine theories; the anxiety and depressive disorder is treated by concerning the morbidity background of the whole disease and the causa morbi and mechanism instead of being treated by the description of the disease; the curative effect is obvious by going deep into the base; the medicine has the same medicine strength as western medicine, so the medicine has no toxic or side effects; the medicine is easily accepted by sufferers; and with the advantages of less crude medicine components, easiness in obtaining, low cost and simple preparation process, the medicine can be popularized and used.
Description
Technical field
The present invention relates to a kind of medicine and application thereof of treating the anxiety-depression obstacle, specifically, is to be the Chinese patent medicine that raw material is processed with the Chinese herbal medicine.
Background technology
Anxiety-depression obstacle (anxiety and depressive disorder) has become the commonly encountered diseases of China.Anxiety disorder refers to a kind of lacking the on tenterhooks of clear and definite object and particular content, and nervous be main anxiety neurosis, patient is insecure all day, worry oneself work, health, are in fear of accident at worry relatives' safety, and often with the body sense of discomfort; Depressive disorder is meant a kind of pessimism and the sense of loss, and is blunt to event response, aprosexia, and expression is sluggish, affective disorder.Simultaneously, anxiety-depression obstacle person 98% all with the insomnia this somatization, sleep is the performance factor of outbalance in the anxiety-depression obstacle.
At present; Doctor trained in Western medicine does not still have final conclusion fully for the etiology and pathogenesis of anxiety-depression obstacle; On its pathogeny, doctor trained in Western medicine thinks that central nervous system's biochemical function is closely related with it unusually, and relates generally to neurotransmitteies such as NE, 5-HT; In addition, think that also anxiety disorder maybe be relevant with Benzodiazepine receptoroid etc.The traditional Chinese medical science not and the corresponding disease name of anxiety-depression obstacle, the anxiety-depression obstacle belongs to the category of traditional Chinese medical science cardiopathia in fact, and is similar with " strongly fragrant disease ", " being insomnia ", " cardiopalmus " in the traditional Chinese medical science, " palpitation with a distress feeling " etc.The traditional Chinese medical science mainly is divided into two aspects, i.e. excess syndrome and deficiency syndrome to the etiology and pathogenesis research of anxiety depressive disorder at present.Excess syndrome mainly contains: is worried excessively, and functional activity of QI being not smooth, the mind is upset in hepatic depression heat-transformation of a specified duration; The stagnation of QI then Tianjin is expectorant with fixed attention, and mental disorder is handed over resistance, lack of preservation of spirit; Feelings will is melancholy, the liver failing to maintain the normal flow of QI, and the gas of having a surplus is fire-transformation with the passing of time, and refining liquid becomes expectorant, and gas, expectorant, heat, knot are hoodwinked the mind; It is depressed to be worried, qi depression to blood stasis, heat-transformation of a specified duration is lit a fire, follow through on disturb malaise then.Except that depression of liver-QI, excessive rising of liver-YANG, liver-wind stirring up internally, but the also disturbance mind causes anxiety.Deficiency syndrome mainly contain: are worried excessively, can cause deficiency of both the heart and spleen, the heart and become homeless fosterly, secretly consume cloudy blood, and the conscience deficiency of YIN-blood, the liver losing its smoothly moving state or liver-yang are high partially, and then soul is difficult to hide, and is refreshing no appended; Liver-blood deficiency then courage is also empty, makes a decision dereliction of duty; The unsuccessful troubled thoughts of feelings will are immoderate, and the QI and blood consumption of the heart is hindered, and can cause courage and lose empty; If undermine cloudy essence, the heart, gallbladder, liver, kidney all can be got involved.The moon is not made sun, and the asthenic fire disturbance makes abnormal mind.
Research finds that also anxiety-depression obstacle and cardiovascular disease are closely related.For example, the nineties in 20th century, the incidence rate of Shanghai Comprehensive hospital outpatient patients ' psychological obstacle was 10% ~ 20%, and the inpatient 20% ~ 50%, and wherein the cardiovascular diseases 40% ~ 50%, mainly is anxiety disorder and depressive disorder; In the crowd that depressed and anxiety disorder are arranged, hypertensive incidence rate increases twice, and the danger of apoplexy, angina pectoris and myocardial infarction increases by 6 times, and mortality rate increases more than the twice.The pathophysiological mechanism that analysis-by-synthesis, depression cause the cardiovascular diseases comprises three aspects at least: the first, cause high steroid 17-hydroxy-11-dehydrocorticosterone mass formed by blood stasis (adrenal cortex is to the reaction aggravation of 17-hydroxy-11-dehydrocorticosterone releasing factor); The second, cause platelet function impaired, comprise that the platelet response degree increases the release of platelet material.The combination of these two kinds of mechanism has constituted the basis of the atherogenic pathophysiological mechanism of depression.The 3rd, patients with depression heart rate variability degree reduces and autonomic nervous dysfunction, causes suffering from arrhythmia person and increases.Anxiety neurosis and coronary heart disease are also closely related, have researcher to think that anxiety patient heart rate variability degree reduces, and the tensile pathologic of reflection vegetative nerve changes.This change causes sympathetic irritation to increase (thereby causing arrhythmia and sudden death), or causes autonomic nervous dysfunction, causes disposition dead.Autonomic nervous dysfunction can cause the cardiac pressure sensitivity reflex function imbalance that is mediated by vegetative nerve and cause sudden death.
From the Pathophysiology pathogenesis of anxiety-depression disease and cardiovascular disease, we can find out clearly that both identical points are with vegetative nerve function closely related.The change that both cause cardiac function all is because autonomic nervous dysfunction causes.In theory, the plus-minus treatment anxiety-depression disease rule of treatment can be to give tranquilizing by nourishing the heart earlier, back liver-smoothing, qi-regulating.Improve the patient autonomic nervous dysfunction with the tranquilizing by nourishing the heart method, improve patient's cardiovascular relevant symptoms and sleep symptom, thus treatment anxiety-depression obstacle.
At present, on the western medical treatment of depression, deanxit is widely used in treating Combination anxiety-depression obstacle.The mixture that deanxit is made up of low dose of flupentixol and low dose of melitracen, its pharmacological action are the results of two kinds of composition comprehensive functions, show that mainly it improves the synaptic space dopamine; The content of various neurotransmitters such as norepinephrine and 5-hydroxytryptamine; Whole central nervous system's function, in addition, it has certain antagonism to histamine's receptor; Has analgesia, anticonvulsant action.It is similar with Benzodiazepines with somatization that the clinical discovery deanxit improves anxiety, but it also has the effect that improves depression preferably.But it limits to part relatively and is that deanxit bans use of in having serious heart disease such as myocardium infarction to recover early stage, bundle branch block; Untreated narrow angle property glaucoma; The patient of fever; Acute alcohol, barbiturate and meconism; Trimester of pregnancy and women breast-feeding their children; Have certain limitation for the medication of intracardiac section, because gerontal patient's bundle branch block is more, most of patients does not have clear and definite main suit, so be prone to cause malpractice.On the traditional Chinese medical science, the medicine of treatment anxiety-depression obstacle is added up its medicine law after deliberation and is: just be followed successively by Poria 39 times by frequency of usage, Radix Glycyrrhizae 31 times, Semen Ziziphi Spinosae 29 times, Radix Bupleuri 25 times; Radix Polygalae 24 times, Radix Angelicae Sinensis 22 times, Fructus Schisandrae Chinensis 19 times, Os Draconis 17 times, Radix Ginseng 16 times; The Radix Paeoniae Alba 16 times, the Rhizoma Pinelliae 16 times, Radix Rehmanniae Preparata 16 times, Radix Rehmanniae 15 times, Radix Ophiopogonis 15 times; Radix Asparagi 15, Radix Salviae Miltiorrhizae 12 times, Semen Platycladi 11 times, Radix Curcumae 11 times, Rhizoma Acori Graminei 11 times.Wherein, the medicine with sedative action has Poria, Semen Ziziphi Spinosae, Radix Polygalae, Fructus Schisandrae Chinensis, Os Draconis, Radix Salviae Miltiorrhizae, Semen Platycladi, Rhizoma Acori Graminei etc., reaches more than 8 flavors; Medicine with replenishing YIN and blood effect has 6 flavors such as Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Rehmanniae Preparata, Radix Rehmanniae, Radix Ophiopogonis, Radix Asparagi; From the utilization rate of said medicine, can know in treatment anxiety-depression obstacle, widely applied calm the nerves, the agent of replenishing YIN and blood, embodied the traditional Chinese medical science and paid attention to treatment this disease irritability primary symptom, take into account the administration features of deficiency of YIN-blood simultaneously.
Chinese patent document CN 200910019713.1; June 15 2011 day for announcing; A kind of Chinese medicine preparation of treating depression, anxiety neurosis and preparation method thereof is disclosed; This Chinese medicine preparation is processed by the important source material of following ratio of weight and number: Radix Rehmanniae Preparata 10-30 part, Flos Albiziae 10-30 part; Semen Platycladi 10-30 part; Rhizoma Cyperi 10-30 part, Radix Bupleuri 10-30 part, Rhizoma Dioscoreae 10-30 part, Radix Polygoni Multiflori Preparata 10-30 part, Herb Gynostemmae Pentaphylli 10-30 part, Fructus Gardeniae 10-30 part, Radix Codonopsis 10-30 part, Radix Angelicae Sinensis 10-30 part, Concha Ostreae 10-30 part, Radix Astragali 10-30 part, Fructus Schisandrae Chinensis 10-30 part, Herba Epimedii 10-30 part, Semen Ziziphi Spinosae 10-30 part, Radix Polygalae 10-30 part, Cortex Phellodendri 10-30 part, Herba Anoectochili roxburghii 10-30 part, Ramulus Uncariae Cum Uncis 10-30 part; Chinese patent document CN 02129417.2; January 26 2005 day for announcing; Disclose a kind of Chinese medicine preparation of treating depression, anxiety neurosis, this Chinese medicine preparation is processed by the following weight proportion raw material: Radix Et Caulis Acanthopanacis Senticosi 10-100 part, Fructus Schisandrae Chinensis 10-100 part, Fructus Gardeniae 5-60 part, Radix Curcumae 3-60 part.The Chinese medicine composition of treatment depressive anxiety obstacle like that has a lot, but shortcoming is more or less all arranged, and for example, flavour of a drug are too much, and the difficulty of drawing materials costs an arm and a leg; Drug effect is not obvious, therapeutic effect difference or the like.Therefore, need a kind of medicine that depressive anxiety obstacle effect is obvious, the flavour of a drug number is moderate, be convenient to prepare of treating badly, still also do not appear in the newspapers about this type medicine at present.
Summary of the invention
The objective of the invention is provides a kind of medicine of treating the depressive anxiety obstacle to deficiency of the prior art.
One purpose more of the present invention is that a kind of purposes of treating the medicine of depressive anxiety obstacle is provided.
For realizing above-mentioned purpose, the technical scheme that the present invention takes is:
A kind of medicine of treating the anxiety-depression obstacle, it mainly is to be processed by following bulk drugs: Radix Bupleuri 6-20 part, Radix Paeoniae Alba 6-20 part, Rhizoma Atractylodis Macrocephalae 6-15 part.
If described drug main is processed by following bulk drugs: Radix Bupleuri 10-16 part, Radix Paeoniae Alba 10-16 part, Rhizoma Atractylodis Macrocephalae 8-12 part.
If described drug main is processed by following bulk drugs: 13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes.
Described medicine also comprises following bulk drugs: Spica Prunellae 6-15 part.
The weight portion of described Spica Prunellae is 8-12 part.
The weight portion of described Spica Prunellae is 10 parts.
Described medicine also comprises following bulk drugs: Rhizoma Coptidis 3-6 part, Cortex Cinnamomi 3-6 part.
The weight portion of described Rhizoma Coptidis is 4.5 parts, and described cinnamomic weight portion is 4.5 parts.
The medicament of described medicine is capsule, granule, tablet, oral liquid, mixture or syrup.
For realizing above-mentioned second purpose, the technical scheme that the present invention takes is:
The application of described medicine in preparation treatment anxiety-depression obstacle medicine.
The invention has the advantages that:
1, medicine of the present invention is based on the competent traditional Chinese medical science and the doctor trained in Western medicine theoretical basis; For the treatment of anxiety-depression obstacle is not only to be directed to the description of disease and to carry out diagnosis and treatment; More be pathogenetic background and the etiology and pathogenesis thereof of paying close attention to whole disease; Go deep into that it is basic, curative effect is obvious, and is well matched in strength with Western medicine;
2, medicine of the present invention is processed by pure Chinese medicine, has no side effect, and is easy to accepted by the patient;
3, medicine material component of the present invention is few, and abundant raw materials is easy to get, low price, and preparation technology is simple, is fit to promote the use of.
Description of drawings
Accompanying drawing 1 is anxiety-depression obstacle age of onset and sickness rate graph of a relation.
Below in conjunction with accompanying drawing the specific embodiment provided by the invention is elaborated.
The preparation (one) of embodiment 1 treatment anxiety-depression obstacle medicine one
6 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (two) of embodiment 2 treatment anxiety-depression obstacle medicines one
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (three) of embodiment 3 treatment anxiety-depression obstacle medicines one
6 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (four) of embodiment 4 treatment anxiety-depression obstacle medicines one
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (five) of embodiment 5 treatment anxiety-depression obstacle medicines one
20 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (six) of embodiment 6 treatment anxiety-depression obstacle medicines one
13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (seven) of embodiment 7 treatment anxiety-depression obstacle medicines one
10 parts of Radix Bupleuri, 16 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (eight) of embodiment 8 treatment anxiety-depression obstacle medicines one
16 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (nine) of embodiment 9 treatment anxiety-depression obstacle medicines one
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (ten) of embodiment 10 treatment anxiety-depression obstacle medicines one
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, conventional method decocts.
The preparation (one) of embodiment 11 treatment anxiety-depression obstacle medicines two
6 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
The preparation (two) of embodiment 12 treatment anxiety-depression obstacle medicines two
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Spica Prunellaes, conventional method decocts.
The preparation (three) of embodiment 13 treatment anxiety-depression obstacle medicines two
6 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
The preparation (four) of embodiment 14 treatment anxiety-depression obstacle medicines two
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
The preparation (five) of embodiment 15 treatment anxiety-depression obstacle medicines two
20 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
The preparation (six) of embodiment 16 treatment anxiety-depression obstacle medicines two
13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Spica Prunellaes, conventional method decocts.
The preparation (seven) of embodiment 17 treatment anxiety-depression obstacle medicines two
10 parts of Radix Bupleuri, 16 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, conventional method decocts.
The preparation (eight) of embodiment 18 treatment anxiety-depression obstacle medicines two
16 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, conventional method decocts.
The preparation (nine) of embodiment 19 treatment anxiety-depression obstacle medicines two
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Spica Prunellaes, conventional method decocts.
The preparation (ten) of embodiment 20 treatment anxiety-depression obstacle medicines two
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, conventional method decocts.
The preparation (one) of embodiment 21 treatment anxiety-depression obstacle medicines three
6 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 3 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (two) of embodiment 22 treatment anxiety-depression obstacle medicines three
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Spica Prunellaes, 6 parts of Rhizoma Coptidis, 3 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (three) of embodiment 23 treatment anxiety-depression obstacle medicines three
6 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 15 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 6 parts of Rhizoma Coptidis, 3 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (four) of embodiment 24 treatment anxiety-depression obstacle medicines three
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 3 parts of Rhizoma Coptidis, 3 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (five) of embodiment 25 treatment anxiety-depression obstacle medicines three
20 parts of Radix Bupleuri, 20 parts of the Radix Paeoniae Albas, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 3 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (six) of embodiment 26 treatment anxiety-depression obstacle medicines three
13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Spica Prunellaes, 4.5 parts of Rhizoma Coptidis, 4.5 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (seven) of embodiment 27 treatment anxiety-depression obstacle medicines three
10 parts of Radix Bupleuri, 16 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 15 parts of Spica Prunellaes, 5 parts of Rhizoma Coptidis, 4 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (eight) of embodiment 28 treatment anxiety-depression obstacle medicines three
16 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, 4 parts of Rhizoma Coptidis, 5 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (nine) of embodiment 29 treatment anxiety-depression obstacle medicines three
20 parts of Radix Bupleuri, 6 parts of the Radix Paeoniae Albas, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Spica Prunellaes, 4 parts of Rhizoma Coptidis, 4 parts of Cortex Cinnamomis, conventional method decocts.
The preparation (ten) of embodiment 30 treatment anxiety-depression obstacle medicines three
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Spica Prunellaes, 5 parts of Rhizoma Coptidis, 6 parts of Cortex Cinnamomis, conventional method decocts.
Need to prove that it is the conventional manufacture method of Chinese medicine decoction that the described conventional method of embodiment 1-30 decocts, and is about to described crude drug decocte with water and becomes decoction.
Embodiment 31 treatment anxiety-depression obstacle medicinal tablet/capsular preparations
Get the arbitrary described medicine of embodiment 1-30, add 9-11 times of water gaging, decocted 2-3.5 hour, leach medicine juice.Add 9 times of water gagings again, decocted 2.5 hours, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 3 times of amounts of concentrated solution ethanol, stirs deposition and spends the night.Get supernatant, be concentrated into thick extractum; Add pharmaceutical aids, vacuum drying is pulverized and is granulated, and is pressed into tablet or fills encapsulated.
The preparation of embodiment 32 treatment anxiety-depression obstacle drug particles
Get the arbitrary described medicine of embodiment 1-30, add 8-10 times of water gaging, decocted 3 hours, leach medicine juice.Add 10 times of water gagings again, decocted 2.5 hours, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 2 times of amounts of concentrated solution ethanol, stirs deposition and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, granulate, drying, granulate gets the 20g granule, packing 10g/ bag.
The preparation of embodiment 33 treatment anxiety-depression obstacle drug mixture/oral liquid/syrups
Get the arbitrary described medicine of embodiment 1-30, add 8-11 times of water gaging, decocted 3 hours, leach medicine juice.Add 8 times of water gagings again, decocted 3 hours, leach medicine juice, merge the secondary decocting liquid, leave standstill, the leaching supernatant concentrates, and puts coldly, adds 3.5 times of amounts of concentrated solution ethanol, stirs deposition and spends the night.Get supernatant, be concentrated into thick extractum; Add suitable pharmaceutical aids, process mixture, oral liquid or syrup.
The clinical trial of embodiment 34 Drug therapy anxiety-depression obstacles of the present invention
1 research data and method
1.1 physical data
Selected case all derives from goes to a doctor in the Shanghai Chinese Medicine Hospital year February in March, 2007-2008, is diagnosed as the anxiety-depression obstacle through Hamilton is depressed with Manifest Anxiety Scale, observes 120 examples altogether.120 examples are divided into 4 groups at random, and every group 30 example is respectively one group of medicine, two groups of medicines, three groups of medicines and deanxit matched group.
One group of maximum age of medicine 84 years old, minimal ages 45 years old, the mean age is 66.58 ± 11.36 years old; Two groups of maximum age of medicine 86 years old, minimal ages 46 years old, the mean age is 64.25 ± 11.07 years old; Three groups of maximum age of medicine 85 years old, minimal ages 46 years old, the mean age is 63.93 ± 10.96 years old; Matched group maximum age 83 years old, minimal ages 46 years old, the mean age is 67.30 ± 10.42 years old.Show that according to the statistics test of normality four groups of P＞0.05, four group data accord with normal distribution are used the t check, four groups of age there was no significant differences, P＞0.05.(seeing table 1).
Four groups of physical data comparisons of table 1 (average ± s)
| ? | The example number | Mean age | The coefficient of skewness | Coefficient of kurtosis |
| One group of medicine | 30 | 66.58±11.36 | 0.51 | 0.86 |
| Two groups of medicines | 30 | 64.25±11.07 | 0.49 | 0.88 |
| Three groups of medicines | 30 | 63.93±10.96 | 0.46 | 0.84 |
| Matched group | 30 | 67.30±10.42 | 0.35 | 0.87 |
Morbidity crowd prevalence according to present embodiment is analyzed, and the relation of age of onset and sickness rate is as shown in Figure 1.As can beappreciated from fig. 1, it is more relatively that 56 years old to 75 years old crowd suffers from anxiety-depression obstacle number, belongs to age bracket occurred frequently, and this provides reference data for later clinical treatment and later clinical trial.
1.2 diagnostic criteria
1.2.1 scale evaluation criteria
1.2.1.1 Hamilton anxiety scale:
1. anxious mood: worry, worry, feel to have the worst thing to take place, easily excitation.
2. nervous: nervous sense, fatiguability, can not loosen, emotional response is prone to cry, trembles, feels uneasy.
3. fear: fear that dark, stranger, a people stay alone, animal, by bus or travelling and the many occasions of people.
4. insomnia: have difficulty in going to sleep, be prone to wake up, sleep deeply, dreaminess, nightmare, fright at night, the back sense of waking up be tired.
5. cognitive function: or claim memory, attention deficit disorder.Attention can not be concentrated, poor memory.
6. depressive mood: forfeiture interest, that hobby is in the past lacked pleasant sensation, melancholy, early awakening, heavy night in daytime is light.
7. musculature symptom: muscular soreness, movable dumb, muscle is twitched, limbs are twitched, One's teeth strike against each other, sound is shaken.
8. sensory system symptom: blurred vision, the heating of feeling cold, weakness sense, twinge from head to foot.
9. cardiovascular system symptom: the beat sense, the sense of fainting, heartbeat of tachycardia, cardiopalmus, chest pain, blood vessel is left out.
10. Respiratory symptoms: uncomfortable in chest, sensation of asphyxia, sigh, dyspnea.
11. gastrointestinal symptom master: dysphagia, belch, dyspepsia (feed back stomachache, stomach burning pain, abdominal distention, feel sick, stomach is full feels), borborygmus, suffer from diarrhoea, lose weight, constipation.
12. urogenital system symptom: ascheturesis, urgent micturition, menolipsis, hyposexuality, ejaculation too early, erect can not, sexual impotence.
13. autonomic nervous system symptom: xerostomia, flushing, pale, be prone to perspire, be prone to " chicken plays pimple ", tension headache, hairs.
14. when talks behavior performance: (1) general performance: nervous, can not relax, uneasy, sting finger, tightly clench fist, fumble handkerchief, facial muscle twitchs, the foot that do not stop, hands shake, frown, express one's feelings stiff, muscular tension is high, sigh kind breathing, pale complexion; (2) physiological performance: swallow, hiccough, resting heart rate are fast, breathe fast (more than 20 times/minute), tendon hyperreflexia, tremble, platycoria, eyelid are beated, be prone to perspire, exophthalmos.
Total points surpasses 29 fens, possibly be serious anxiety; Surpass 21 fens, obvious anxiety is arranged certainly; Surpass 14 fens, anxiety is arranged certainly; Surpass 7 fens, have anxiety; As less than 6 minutes, patient does not just have anxiety symptom.
1.2.1.2 Hamilton depressive scale:
1. depressive emotion: (1) is only just told when asking; (2) in interview, spontaneously express; (3) betray this emotion also can or desiring to cry without speech from expression, posture, sound; (4) patient's spontaneous speech and non-language performance (expression, action) almost completely show as this emotion.
2. guilty sense: (1) blame oneself, feel that oneself has involved other people; (2) think and oneself violated crime, or in the past the mistake of the ruminating over mistake of becoming estranged; (3) think and be present disease to own wrong punishment, or delusion of sin is arranged; (4) delusion of sin is with scolding or the menace hallucination.
3. commit suiside: (1) feels to live nonsensical; (2) hope oneself to die, or often expect and dead relevant thing; (3) passive idea (suicidal thought); (4) serious suicide is arranged.
4. difficulty falling asleep (just section insomnia): there is difficulty falling asleep in (1) main suit, still can not fall asleep after the half an hour of going to bed.(will note the time that patient at ordinary times falls asleep); (2) main suit all has difficulty falling asleep every night.
5. insomnia-middle (stage casing insomnia): (1) sleep is shallow, many nightmares; (2) midnight, (before late 12 o'clock) once woke up (do not comprise and going to toilet).
6. early awakening (latter end insomnia): (1) has early awakening, and early awakening is 1 hour than usual, but can fall asleep again (should get rid of custom at ordinary times); (2) can't fall asleep again behind the early awakening.
7. work and interest: just tell when put question to (1); (2) spontaneously direct or indirect the expression loses interest to activity, work or study, as feels listless, and be irresolute, can not adhere to maybe need forcing work or the activity of oneself going; (3) activity time reduces or effect decline, and the inpatient participates in the ward work every day or amusement is discontented with 3 hours; (4) because of present disease quits work, the hospitalizing does not participate in any activity or does not have other people to help just can not accomplish ward routine matter (notes all can not be in hospital just made a call to 4 fens).
8. retardance (refer to thinking and bradyphrasia, attention is difficult to concentrate, and initiative goes down): find slight retardance in (1) interview; (2) find obviously retardance in the interview; (3) difficulty is carried out in interview; (4) can not answer a question fully (numb).
9. intense: restless a bit during (1) inspection; (2) obviously restless or little trick is many; (3) can not sit quietly, once stand up in the inspection; (4) rub hands, sting finger, pull hair, bite one's lips.
10. spirituality anxiety: (1) is told when asking about; (2) spontaneously express; (3) expression and talk are betrayed obvious melancholy worry; (4) obviously terrified.
11. somatic anxiety (refer to the physiological signs of anxiety, comprising: xerostomia, abdominal distention, diarrhoea, hiccough, angina abdominis, cardiopalmus, headache, Hyperventilation and sigh, and frequent micturition and perspiration): (1) is slight; (2) moderate has sure above-mentioned symptom; (3) severe, above-mentioned symptom is serious, and the influence life maybe needs to handle; (4) have a strong impact on life and movable.
12. gastrointestinal symptom: (1) loss of appetite, but do not need other people to encourage just to take food voluntarily; (2) feed needs other people to urge or asks and needs application cathartic or digestant.
13. General Symptoms: (l) extremity, back or cervical region sense of heaviness, backache, headache, myalgia, malaise or tired; (2) symptom is obvious.
14. property symptom (referring to hyposexuality, menoxenia etc.): (1) is slight; (2) severe; (3) can not affirm, or this item is to being not suitable for (being not counted in total points) by the person of commenting.
15. hypochondriasis: (1) is too paid close attention to health; (2) turn over health problem; (3) nosomania is arranged; (4) nosomania of companion's hallucination.
16. lose weight: evaluate by medical history: (1) patient tells to have and loses weight; (2) lose weight certainly.Evaluate by the body weight record: lose weight in (1) one week above 0.5 kilogram; Lose weight above 1 kilogram in (2) one weeks.
17. insight: (0) is known own ill, shows as depression; (1) know that oneself is ill, but it is too poor to lay the blame on messes, environmental problem, it is busy to work, and viral infection maybe needs to have a rest; (2) deny fully ill.
Total points surpasses 24 fens, possibly be major depression; Surpassing 17 fens, possibly be the depression of light or medium degree; As less than 7 minutes, patient does not just have depressive symptom.
1.2.2 integration evaluation
(1) symptom is slight;
(2) sure symptom is arranged, but do not influence life with movable;
(3) severe symptoms need add processing, or has influenced life activity;
(4) symptom is extremely heavy, has a strong impact on its life.
1.3 observe the case standard
1.3.1 the standard of including in:
Age, sanity can clearly be expressed own wish greater than 18 years old, and the men and women does not limit.
Meet Hamilton depressive scale (HAMD) 17 item ratings >=17 minutes, or >=14 minutes patient of HAS (HAMA) evaluation.Estimate to include in altogether 120 routine patients.
1.3.2 exclusion standard:
Do not meet the primary disease diagnostic criteria; Internal diseases such as the serious organic heart, liver, kidney, endocrine, blood are arranged; Serious suicidal tendency is arranged, ethanol and drug dependence person are arranged, arranged age of sucking, gestation or might be the conceived women of duration of test; The patient who medicine is had allergies; IQ defectiveness person.
The standard 1.3.3 come off:
Compliance is poor, can not take medicine according to test method, and the dosing or the person of changing dressings midway transfer to manic or the person that has the suicidal tendency during the treatment.(medicine is included 31 examples in for one group, and wherein 1 example comes off; Medicine is included 32 examples in for two groups, and wherein 2 examples come off; Medicine is included 33 examples in for three groups, and wherein 3 examples come off; Matched group is included 32 examples in, and wherein 2 examples come off)
1.4 observational technique
1.4.1 divide into groups and administration
Divide 4 groups at random through the screening eligible, three groups of medicines of taking embodiment 6, embodiment 16 and embodiment 26 preparations respectively every day of one group of medicine, two groups of medicines and medicine, decoct to concentration for containing crude drug amount 0.25g/mL, each decoction of morning and evening is once taken 100mL at every turn; Matched group is taken 1 deanxit, once a day.Medicining cycle was 6 weeks.Forbid taking other kinds psychosis, antidepressant antianxiety drugs during the research.
1.4.2 clinical observation
Testing for first week and testing for the 6th week, observe patient's symptom respectively, vital sign.With Hamilton depressive scale (HAMD), Hamilton anxiety scale (HAMA) evaluation.
1.5 observation index
Observe patient's blood pressure, heart rate, the rhythm of the heart and main suit when going to a doctor.
Itemized record patient takes the untoward reaction situation of medicine, comprises time of origin, clinical symptoms, persistent period, treatment measures and extinction time.
1.6 curative effect judgment criteria
As main evaluation index, judge curative effect with Hamilton depressive scale and Hamilton anxiety scale with the branch rate that subtracts of Hamilton scale.
Subtract branch rate=(baseline total points-treatment back total points)/baseline total points
Subtract branch rate >=50% and be produce effects, >=30% for taking a turn for the better, and＜30% is invalid.
Clinical produce effects+improvement=total effective rate
1.7 statistical method
With SPSS 13.0 statistical softwares, enumeration data is used χ
2Check, measurement data is checked with t, P<0.05 for statistical significance is arranged.
2 results
2.1 situation before four groups of treatments
Four groups of patients are before treatment, and anxiety integration and depressed integration be all through statistical test, anxiety integration P=0.30, depressed integration P=0.83, four P＞0.05 relatively, be presented at treatment before, severity extent of each group does not have significant difference.(seeing table 2)
The state of an illness relatively before four groups of treatments of table 2
2.2 the comparable situation of four groups of treatment front and back
One group of patient anxiety of medicine treats foreset and is divided into 17.36 ± 2.94 fens, is 9.75 ± 2.16 minutes after the treatment, through statistical analysis, and t=14.58, P ﹤ 0.01; Integration was 14.41 ± 2.63 minutes before depression was treated, treatment back 9.78 ± 2.92, and t=7.89, P ﹤ 0.01, medicine is described, and one group there were significant differences before and after treating anxiety and depressive disorder, treating.
Two groups of patient anxieties of medicine treat foreset and are divided into 17.50 ± 2.91 fens, are 9.70 ± 2.25 minutes after the treatment, through statistical analysis, and t=15.77, P ﹤ 0.01; Integration was 13.83 ± 2.80 minutes before depression was treated, treatment back 8.73 ± 2.42, and t=9.45, P ﹤ 0.01, medicine is described, and two groups there were significant differences before and after treating anxiety and depressive disorder, treating.
Three groups of patient anxieties of medicine treat foreset and are divided into 18.32 ± 2.33 fens, are 10.61 ± 2.41 minutes after the treatment, through statistical analysis, and t=16.71, P ﹤ 0.01; Integration was 13.43 ± 2.81 minutes before depression was treated, treatment back 8.93 ± 2.57, and t=8.78, P ﹤ 0.01, medicine is described, and three groups there were significant differences before and after treating anxiety and depressive disorder, treating.
The matched group patient anxiety treats foreset and is divided into 18.33 ± 2.48 fens, is 10.23 ± 2.14 minutes after the treatment, through statistical analysis, and t=20.74, P ﹤ 0.01; Integration is 14.43 ± 2.75 minutes before the depressed treatment, treatment back 9.93 ± 2.23, and t=13.18, P ﹤ 0.01 explains matched group at treatment anxiety and depressive disorder, also there were significant differences before and after the treatment.
Compare between group, treatment group and treatment of control group anxiety disorder, four groups show P=0.35 through statistical analysis, P＞0.05, no significant difference.Treatment group and treatment of control group depressive disorder, four groups show P=0.11 through statistical analysis, P＞0.05, no significant difference.(seeing table 3)
Integration contrast before and after four groups of treatments of table 3
According to the curative effect that subtracts after the branch rate is evaluated treatment, subtract branch rate >=50% and be produce effects, >=30% for taking a turn for the better, and＜30% is invalid.The efficacy evaluation result sees table 4 behind four groups of patient treatments.Through statistical analysis, P ﹥ 0.05 explains the total effective rate no significant difference of three groups of one group of medicines, two groups of medicines, medicine and treatment of control group anxiety-depression obstacle.
Four groups of efficacy evaluation contrasts of table 4
2.3 four groups of relevant symptoms integrations relatively
2.3.1 the heart correlation intergal relatively
The heart correlation intergal is relatively used the integration of Hamilton anxiety scale the 9th, 10, and two integrations comprise the symptoms such as sense, the sense of fainting, heartbeat are omitted, uncomfortable in chest, sensation of asphyxia, sigh, dyspnea of beating tachycardia, cardiopalmus, chest pain, blood vessel.
Preceding 2.98 ± 1.23 minutes of one group of treatment of medicine, treatment back 1.18 ± 0.85 minutes, t=8.09, P ﹤ 0.01 explains that there were significant differences before and after the treatment; Preceding 2.91 ± 1.06 minutes of two groups of treatments of medicine, treatment back 1.06 ± 0.93 minutes, t=10.05, P ﹤ 0.01 explains that there were significant differences before and after the treatment; Preceding 3.13 ± 1.13 minutes of three groups of treatments of medicine, treatment back 1.17 ± 0.91 minutes, t=9.29, P ﹤ 0.01 explains that there were significant differences before and after the treatment; Preceding 2.63 ± 1.54 minutes of treatment of control group, treatment back 1.00 ± 0.87 minutes, t=7.35, P ﹤ 0.01 explains that also there were significant differences before and after the treatment; Can find out obviously that from the change of dividing equally in the improvement situation of heart integration, the improvement situation that medicine is three groups will be than matched group good (seeing table 5).But four compare, P ﹥ 0.05, and one group of medicine, two groups of medicines, three groups of medicines and matched group are not having significant difference aspect the treatment heart relevant symptoms.
Table 5 heart correlation-integral Analysis
2.3.2 the sleep correlation intergal relatively
The sleep correlation intergal is relatively used Hamilton anxiety scale the 5th, the integration of Hamilton depressive scale the 4th, 5, and these 3 contents comprise sleeping obstacle, Depth of sleep, sleep quality.
Preceding 5.43 ± 2.09 minutes of one group of treatment of medicine, treatment back 2.95 ± 1.78 minutes, t=6.85, P ﹤ 0.01 explains that there were significant differences before and after the treatment; Preceding 5.29 ± 2.11 minutes of two groups of treatments of medicine, treatment back 2.74 ± 1.90 minutes, t=6.69, P ﹤ 0.01 explains that there were significant differences before and after the treatment; Preceding 5.63 ± 2.14 minutes of three groups of treatments of medicine, treatment back 2.93 ± 1.63 minutes, t=7.08, P ﹤ 0.01 explains that there were significant differences before and after the treatment; Preceding 4.80 ± 2.41 minutes of treatment of control group, treatment back 3.13 ± 1.90 minutes, t=6.65, P ﹤ 0.01 explains that also there were significant differences before and after the treatment; Can obviously find out from the difference that improve four groups of sleep front and back; The improvement situation that one group of medicine, two groups of medicines and medicine are three groups is obviously good a lot of than matched group; The total effective rate of matched group is 53.33%, and the total effective rate that one group of medicine, two groups of medicines and medicine are three groups is respectively 63.33%, 66.67% and 70% (seeing table 6,7), and four differences of sleeping are compared; P ﹤ 0.05, one group of medicine, two groups of medicines, three groups of medicines and matched group are described, and there were significant differences aspect improvement sleep relevant symptoms.
Table 6 sleep correlation-integral Analysis
Table 7 sleep efficacy evaluation
| ? | The example number | Produce effects | Take a turn for the better | Invalid | Total effective rate |
| Matched group | 30 | 3 | 13 | 14 | 53.33% |
| One group of medicine | 30 | 4 | 15 | 11 | 63.33% |
| Two groups of medicines | 30 | 4 | 16 | 10 | 66.67% |
| Three groups of medicines | 30 | 5 | 16 | 9 | 70.0% |
2.3.3 sleep and anxiety, depressed degree of association are relatively
Add up this 120 routine patient and obtain sleep and anxiety, depressed degree of association, comparative result is seen table 8.Can clearly find out from table 8, though the P value of sleep and anxiety and depression all less than 0.05, thinks that sleep and anxiety-depression obstacle are proportionate.But from table, can find out, sleep and depressed degree of association P ﹤ 0.01, sleep and anxiety degree of association P ﹤ 0.05, visible sleep is more relevant with depressive disorder.
Table 8 sleep and anxiety, depressed degree of association are relatively
| ? | The example number | Correlation coefficient | The P value |
| Sleep and depressive disorder degree of association | 120 | 0.555 | 0.000 |
| Sleep and anxiety disorder degree of association | 120 | 0.288 | 0.026 |
2.4 safety analysis
Four groups untoward reaction do not occur during treating, the nausea and vomiting of appearance gastrointestinal symptom is not arranged, the yet asymptomatic case that sharply increases the weight of.
Present embodiment has been broken through research mode in the past, courageously uses present very effective deanxit to experimentize as matched group, has proved in treatment anxiety-depression obstacle field; Medicine of the present invention and Western medicine deanxit are well matched in strength; But more can regulate cardiac function effectively, in addition, medicine of the present invention is pure Chinese medicine; Can not produce drug dependence and safe without toxic side effect, accepted by the patient easily.
Why evident in efficacy medicine of the present invention is, is because it is based on the competent traditional Chinese medical science and the doctor trained in Western medicine theoretical basis tranquilizing by nourishing the heart, liver-smoothing, qi-regulating.Specifically, Radix Bupleuri property is bitter, be slightly cold, and is the key medicine of depressed liver-energy dispersing and QI regulating, promoting the circulation of QI to relieve pain, can resist the spasm of gastrointestinal smooth muscle on the one hand, can expand peripheral vessels and blood pressure lowering again on the other hand; Radix Paeoniae Alba bitter in the mouth, flat; Tool nourishing blood to suppress the hyperactive liver, slow middle pain relieving, yin fluid astringing are received the effect of antiperspirant; Scientific research shows that also it has couple central nervous system that inhibitory action is arranged, and mouse peritoneal injection paeoniflorin can reduce spontaneous activity; Prolong the length of one's sleep of ciclobarbital soluble, suppress due to caused writhing response of lumbar injection acetic acid and antagonism pentylenetetrazole, to faint from fear; The Rhizoma Atractylodis Macrocephalae is bitter, sweet, warm, and invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis can be adjusted gastrointestinal motility function, enhancing human body immunity power; Spica Prunellae is bitter, hot, cold, can relieve inflammation or internal heat make eye bright, blood pressure lowering, mass dissipating and swelling eliminating; Rhizoma Coptidis is bitter, cold, nontoxic, heat clearing and damp drying, eliminating fire and detoxication; Its sweet in the mouth of Cortex Cinnamomi, suffering, big heat, owner's kidney channel, the property master is descending, but the merit guiding fire to origin.Therefore says that not to be laser accunputure for the treatment of anxiety-depression obstacle carry out diagnosis and treatment for the description of card to medicine of the present invention, more is the pathogenetic background and the etiology and pathogenesis thereof of the whole disease of concern, go deep into that it is basic, be the basis to effect a permanent cure.
The above only is a preferred implementation of the present invention; Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; Can also make some improvement and replenish, these improvement and replenish and also should be regarded as protection scope of the present invention.
Claims (10)
1. a medicine of treating the anxiety-depression obstacle is characterized in that, it mainly is to be processed by following bulk drugs: Radix Bupleuri 6-20 part, Radix Paeoniae Alba 6-20 part, Rhizoma Atractylodis Macrocephalae 6-15 part.
2. medicine according to claim 1 is characterized in that, it mainly is to be processed by following bulk drugs: Radix Bupleuri 10-16 part, Radix Paeoniae Alba 10-16 part, Rhizoma Atractylodis Macrocephalae 8-12 part.
3. medicine according to claim 1 is characterized in that, it mainly is to be processed by following bulk drugs: 13 parts of Radix Bupleuri, 13 parts of the Radix Paeoniae Albas, 10 parts of the Rhizoma Atractylodis Macrocephalaes.
4. medicine according to claim 1 is characterized in that, it also comprises following bulk drugs: Spica Prunellae 6-15 part.
5. medicine according to claim 5 is characterized in that, the weight portion of described Spica Prunellae is 8-12 part.
6. according to claim 4 or 5 described medicines, it is characterized in that the weight portion of described Spica Prunellae is 10 parts.
7. medicine according to claim 4 is characterized in that, it also comprises following bulk drugs: Rhizoma Coptidis 3-6 part, Cortex Cinnamomi 3-6 part.
8. medicine according to claim 7 is characterized in that, the weight portion of described Rhizoma Coptidis is 4.5 parts, and described cinnamomic weight portion is 4.5 parts.
9. according to claim 1,4 or 7 described medicines, it is characterized in that the medicament of described medicine is capsule, granule, tablet, oral liquid, mixture or syrup.
10. according to claim 1,4 or 7 described medicines, it is characterized in that the application of described medicine in preparation treatment anxiety-depression obstacle medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210005314.1A CN102552436B (en) | 2012-01-10 | 2012-01-10 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210005314.1A CN102552436B (en) | 2012-01-10 | 2012-01-10 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552436A true CN102552436A (en) | 2012-07-11 |
| CN102552436B CN102552436B (en) | 2014-05-07 |
Family
ID=46399891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210005314.1A Expired - Fee Related CN102552436B (en) | 2012-01-10 | 2012-01-10 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552436B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105381015A (en) * | 2015-11-26 | 2016-03-09 | 天津中医药大学 | Traditional Chinese medicine composition with anti-depression function and preparation method thereof |
| CN106362078A (en) * | 2016-11-04 | 2017-02-01 | 上海市中医医院 | Antianxiety traditional Chinese medicine composition and application thereof |
| CN112426503A (en) * | 2019-11-29 | 2021-03-02 | 王宇红 | Traditional Chinese medicine composition for treating depression |
| CN113663009A (en) * | 2020-05-13 | 2021-11-19 | 鹤壁市人民医院 | Pharmaceutical composition for regulating nerves as well as preparation method and application thereof |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1123357C (en) * | 1999-06-25 | 2003-10-08 | 刘永香 | Powdered medicine for conditioning viscera and whole body |
| CN1810274A (en) * | 2005-01-28 | 2006-08-02 | 郑乐建 | Cassia, its extract cinnamal and their application in preparing medicine for treating depression |
| CN101244244A (en) * | 2008-03-05 | 2008-08-20 | 四川省中医药科学院 | Depression treating medicine composition and preparation method thereof |
| US20090226482A1 (en) * | 2008-03-04 | 2009-09-10 | Hei Ling Helen Chan | Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same |
| CN101711847A (en) * | 2009-12-08 | 2010-05-26 | 中国人民解放军第三医院 | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis |
| CN101411800B (en) * | 2008-12-01 | 2010-12-29 | 唐振坤 | Medicament for treating anxiety symptoms |
| CN102008561A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Mixture for treating depression |
| CN102058691A (en) * | 2010-11-23 | 2011-05-18 | 河南中医学院 | Application of coptis and alkaloid thereof in preparation of anti-anxiety medicament |
| CN102078520A (en) * | 2011-01-10 | 2011-06-01 | 董春玲 | Chinese medicinal preparation for treating nervous headache and preparation method thereof |
| CN102133378A (en) * | 2011-03-23 | 2011-07-27 | 何玉伟 | Medicament for treating breast cancer |
| CN102139086A (en) * | 2011-04-09 | 2011-08-03 | 河南中医学院 | Traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression |
| CN102283910A (en) * | 2011-08-05 | 2011-12-21 | 浙江省中医药研究院 | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof |
| CN102319406A (en) * | 2011-10-10 | 2012-01-18 | 张运林 | Medicament for treating tristimania |
| CN102406894A (en) * | 2011-11-08 | 2012-04-11 | 文登市口腔医院米山路口腔诊所 | Chinese medicine for treating premenstrual syndrome |
| CN102406821A (en) * | 2011-10-26 | 2012-04-11 | 文登市口腔医院 | Traditional Chinese medicine for treating simple goiter |
| CN102416145A (en) * | 2011-12-07 | 2012-04-18 | 荣成市科学技术情报研究所 | Chinese medicinal composition for treating menstrual disorder |
| CN102580019A (en) * | 2011-01-14 | 2012-07-18 | 天津市中宝制药有限公司 | Chinese medicinal composition for treating reflux esophagitis |
-
2012
- 2012-01-10 CN CN201210005314.1A patent/CN102552436B/en not_active Expired - Fee Related
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1123357C (en) * | 1999-06-25 | 2003-10-08 | 刘永香 | Powdered medicine for conditioning viscera and whole body |
| CN1810274A (en) * | 2005-01-28 | 2006-08-02 | 郑乐建 | Cassia, its extract cinnamal and their application in preparing medicine for treating depression |
| US20090226482A1 (en) * | 2008-03-04 | 2009-09-10 | Hei Ling Helen Chan | Herbal composition for treatment of insomnia and other related disorders and a method of preparing the same |
| CN101244244A (en) * | 2008-03-05 | 2008-08-20 | 四川省中医药科学院 | Depression treating medicine composition and preparation method thereof |
| CN101411800B (en) * | 2008-12-01 | 2010-12-29 | 唐振坤 | Medicament for treating anxiety symptoms |
| CN101711847A (en) * | 2009-12-08 | 2010-05-26 | 中国人民解放军第三医院 | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis |
| CN102058691A (en) * | 2010-11-23 | 2011-05-18 | 河南中医学院 | Application of coptis and alkaloid thereof in preparation of anti-anxiety medicament |
| CN102008561A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Mixture for treating depression |
| CN102078520A (en) * | 2011-01-10 | 2011-06-01 | 董春玲 | Chinese medicinal preparation for treating nervous headache and preparation method thereof |
| CN102580019A (en) * | 2011-01-14 | 2012-07-18 | 天津市中宝制药有限公司 | Chinese medicinal composition for treating reflux esophagitis |
| CN102133378A (en) * | 2011-03-23 | 2011-07-27 | 何玉伟 | Medicament for treating breast cancer |
| CN102139086A (en) * | 2011-04-09 | 2011-08-03 | 河南中医学院 | Traditional Chinese medicine for treating liver constraint and spleen deficiency type post-stroke depression |
| CN102283910A (en) * | 2011-08-05 | 2011-12-21 | 浙江省中医药研究院 | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof |
| CN102319406A (en) * | 2011-10-10 | 2012-01-18 | 张运林 | Medicament for treating tristimania |
| CN102406821A (en) * | 2011-10-26 | 2012-04-11 | 文登市口腔医院 | Traditional Chinese medicine for treating simple goiter |
| CN102406894A (en) * | 2011-11-08 | 2012-04-11 | 文登市口腔医院米山路口腔诊所 | Chinese medicine for treating premenstrual syndrome |
| CN102416145A (en) * | 2011-12-07 | 2012-04-18 | 荣成市科学技术情报研究所 | Chinese medicinal composition for treating menstrual disorder |
Non-Patent Citations (5)
| Title |
|---|
| 刘冬等: "半夏夏枯草合剂对慢性应激抑郁模型大鼠血清皮质醇的影响", 《贵阳中医学院学报》 * |
| 吴琨等: "交泰丸抗抑郁作用的药理实验研究", 《贵阳中医学院学报》 * |
| 方善光: "痛泻要方加味治疗肠道易激综合征", 《中国中医药信息杂志》 * |
| 王静: "调和肠激停汤治疗肠易激综合征35例疗效观察", 《河北中医》 * |
| 赵江丽等: "夏枯草镇静与催眠作用的初步研究", 《时珍国医国药》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105381015A (en) * | 2015-11-26 | 2016-03-09 | 天津中医药大学 | Traditional Chinese medicine composition with anti-depression function and preparation method thereof |
| CN106362078A (en) * | 2016-11-04 | 2017-02-01 | 上海市中医医院 | Antianxiety traditional Chinese medicine composition and application thereof |
| CN112426503A (en) * | 2019-11-29 | 2021-03-02 | 王宇红 | Traditional Chinese medicine composition for treating depression |
| CN112426503B (en) * | 2019-11-29 | 2022-09-23 | 王宇红 | Traditional Chinese medicine composition for treating depression |
| CN113663009A (en) * | 2020-05-13 | 2021-11-19 | 鹤壁市人民医院 | Pharmaceutical composition for regulating nerves as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552436B (en) | 2014-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101766791B (en) | Chinese herbal composite for fever treatment and preparation method thereof | |
| CN101670076B (en) | Traditional Chinese medicine composition for treating disease of chronic nephritis and preparation method thereof | |
| CN101785823B (en) | Traditional Chinese medicine combination and preparation method for malaise, palpitation and insomnia treatment | |
| CN101711850B (en) | Traditional Chinese medicine composition for treating symptoms of myocardial ischemia, palpitation and severe palpitation and preparation method | |
| CN101698090B (en) | Traditional Chinese medicine composite for treating coma and heart syncope symptoms and preparation method thereof | |
| CN101757528A (en) | Traditional Chinese medicine composition for treating symptoms of deficiency of kidney yin and soreness and weakness of waist and knees and preparation method thereof | |
| CN102526474B (en) | Chinese medicine composition for treating neurasthenia | |
| CN101773650A (en) | Chinese medicinal composition for treating clonic convulsion and preparation method thereof | |
| CN103800639A (en) | Medicinal composition with blood glucose reducing, blood lipid reducing and blood pressure lowering effects | |
| CN102240380B (en) | Traditional Chinese medicine preparation for treating senile vascular dementia | |
| CN105477263A (en) | Tea capable of tonifying qi, spleen and kidney | |
| CN101670060A (en) | Traditional Chinese medicine composition for treating such diseases as hepatic stagnation, chest stuffiness and distension and preparation method | |
| CN102973685A (en) | Anti-fatigue traditional Chinese medicine preparation and preparation method thereof | |
| CN101711847B (en) | Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis | |
| CN101780245A (en) | Traditional Chinese medicine composition for treating senile dementia and preparation method thereof | |
| CN102552436B (en) | Medicine for treating anxiety and depressive disorder as well as application of medicine | |
| CN103520640B (en) | Traditional Chinese medicine for treating depression | |
| CN101810787B (en) | Chinese medicinal composition for treating dysphoria and preparation method thereof | |
| CN101711853B (en) | Traditional Chinese medicine composition for treating symptoms of bradycardia and preparation method thereof | |
| CN101791348B (en) | Traditional Chinese medicine preparation for treatment of deficiency of five viscera | |
| CN102579816A (en) | Brain-invigorating tablets and preparation method thereof | |
| CN101972430A (en) | Traditional Chinese medicament composition for treating dreamed coitus of woman and preparation method thereof | |
| CN101773652A (en) | Chinese medicine composition for treating amnesia and preparation method thereof | |
| CN101549124A (en) | Pharmaceutical composition for nourishing heart, tranquillization, strengthening spleen and benefiting qi and preparation method thereof | |
| CN104906551A (en) | Anti-fatigue traditional Chinese medicine, food composition and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140507 Termination date: 20160110 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |